Sahu, A Athena Soulika Morikis, D Spruce, L Moore, Wt Lambris, Jd
Published in
The Journal of Immunology
We have previously identified a 13-residue cyclic peptide, Compstatin, that binds to complement component C3 and inhibits complement activation. Herein, we describe the binding kinetics, structure-activity relationship, and biotransformation of Compstatin. Biomolecular interaction analysis using surface-plasmon resonance showed that Compstatin boun...
Fujita, M Takada, Yk Yoshikazu Takada
Published in
The Journal of Immunology
The membrane-bound chemokine fractalkine (FKN, CX3CL1) on endothelial cells plays a role in leukocyte trafficking. The chemokine domain (FKN-CD) is sufficient for inducing FKN signaling (e.g., integrin activation), and FKN-CD binds to its receptor CX3CR1 on leukocytes. Whereas previous studies suggest that FKN-CD does not directly bind to integrins...
Rudolph, M Hebel, K Miyamura, Y Emanual Maverakis Brunner-Weinzierl, Mc
Published in
The Journal of Immunology
CTLA-4 is known as a central inhibitor of T cell responses. It terminates T cell activation and proliferation and induces resistance against activation induced cell death. However, its impact on memory formation of adaptive immune responses is still unknown. In this study, we demonstrate that although anti-CTLA-4 mAb treatment during primary immuni...
Alvarez, M Sungur, Cm Erik Ames Anderson, Sk Pomeroy, C William Murphy
Published in
The Journal of Immunology
NK subsets have activating and inhibitory receptors that bind MHC-I. Ly49A is a mouse inhibitory receptor that binds with high affinity to H2(d) in both a cis- and trans-manner. Ly49A cis-associations limit trans-interactions with H2(d)-expressing targets as well as mAb binding. We demonstrate that cis-interactions affect mAb effector functions. In...
Weiss, Jm Subleski, Jj Back, T Chen, X Watkins, Sk Yagita, H Sayers, Tj William Murphy Wiltrout, Rh
Published in
The Journal of Immunology
Fas ligand expression in certain tumors has been proposed to contribute to immunosuppression and poor prognosis. However, immunotherapeutic approaches may elicit the Fas-mediated elimination of immunosuppressive regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) within tumors that represent major obstacles for cancer immunother...
Erik Ames Canter, Rj Grossenbacher, Sk Mac, S Chen, M Smith, Rc Hagino, T Perez-Cunningham, J Gail Sckisel Urayama, S
...
Published in
The Journal of Immunology
Increasing evidence supports the hypothesis that cancer stem cells (CSCs) are resistant to antiproliferative therapies, able to repopulate tumor bulk, and seed metastasis. NK cells are able to target stem cells as shown by their ability to reject allogeneic hematopoietic stem cells but not solid tissue grafts. Using multiple preclinical models, inc...
Alvarez, M Bouchlaka, Mn Gail Sckisel Sungur, Cm Chen, M William Murphy
Published in
The Journal of Immunology
Because of increasing interest in the removal of immunosuppressive pathways in cancer, the combination of IL-2 with Abs to neutralize TGF-β, a potent immunosuppressive cytokine, was assessed. Combination immunotherapy resulted in significantly greater antitumor effects. These were correlated with significant increases in the numbers and functionali...
Athena Soulika Morikis, D Sarrias, Mr Roy, M Spruce, La Sahu, A Lambris, Jd
Published in
The Journal of Immunology
Compstatin, a 13-mer cyclic peptide, is a novel and promising inhibitor of the activation of the complement system. In our search for a more active analog and better understanding of structure-functions relations, we designed a phage-displayed random peptide library based on previous knowledge of structure activity relations, in which seven amino a...
Kozlowski, Lm Athena Soulika Silverman, Gj Lambris, Jd Levinson, Ai
Published in
The Journal of Immunology
Staphylococcal protein A (SpA), acting as a B cell superantigen, binds to the Fab region of human VH3+ Igs. Using SpA abrogated of its IgG Fc binding activity (Mod SpA) as a model B cell superantigen, we determined whether such an interaction causes complement activation. Addition of Mod SpA to human serum led to complement consumption and the gene...
Sahu, A Isaacs, Sn Athena Soulika Lambris, Jd
Published in
The Journal of Immunology
Vaccinia virus complement control protein (VCP) is a virulence determinant of vaccinia virus that helps protect the virus from the complement attack of the host. To characterize the interaction of VCP with C3 and C4 and understand the mechanism by which VCP inactivates complement, we have expressed VCP in a yeast expression system and compared the ...
